Nemaura Medical Inc (NMRD) is a medical technology company focused on developing non-invasive wearable diagnostic devices and consumer health products. The company's lead product is a continuous glucose monitoring system (CGM) called sugarBEAT, which provides glucose readings for people with diabetes.
The sugarBEAT device is worn on the skin and uses a small, disposable patch to measure glucose levels in the interstitial fluid, which is the fluid between cells in the body. The data is then transmitted to a mobile app, allowing users to monitor their glucose levels in real-time.
Nemaura Medical has also developed other wearable health monitoring devices, such as a temperature monitoring patch and a lactate monitoring patch for athletes. The company is focused on developing a range of non-invasive, wearable diagnostic devices that can be used in a variety of healthcare settings.
In addition to its wearable technology products, Nemaura Medical is also developing a range of consumer health products, such as a non-invasive weight management system that helps people track their daily caloric intake.
The company is headquartered in Loughborough, UK and has a subsidiary in the United States. Nemaura Medical Inc. is listed on the NASDAQ stock exchange under the ticker symbol NMRD.
|
